Patent of the Week: A Predictive Gene Signature for Breast Cancer Therapy

Patent of the Week

Inventors, including University of Chicago researcher Edwardine Labay, have patented a seven-gene signature that can be used to assess the risk of breast cancer progression and treatment response.

The invention covers a tumor characterization method as well as a method for identifying the gene signature marker. It also includes a “kit” for performing the method of characterizing a tumor.

“Individualization of cancer management requires prognostic markers and therapy-predictive markers,” the researchers explained in a paper. “Prognostic markers assess risk of disease progression independent of therapy, whereas therapy-predictive markers identify patients whose disease is sensitive or resistant to treatment.”

Additionally, as most cancer treatments have undesirable side effects, using predictive markers eliminates “unnecessary risk of adverse side effects by reducing administration of cancer treatments to individuals for whom treatment is likely to fail.”

// Read more:

// Patent of the Week is a weekly column highlighting research and inventions from University of Chicago faculty.

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.